ALK+ anaplastic large cell lymphoma (ALCL) has a 5-year overall survival of ~70% but for the other common PTCL subtypes (ALK- ALCL, angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)) the clinical outlook is poor (5-year overall survival ~35%) [1]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.